Why the first hours matter

Giant cell arteritis matters because inflammation in a medium or large artery can become an eye emergency before a diagnostic workup is complete. In patients older than 50 with a new headache, jaw pain while chewing, scalp tenderness, or sudden visual symptoms, the question is not simply “Could this be migraine?” It is “Could this be vasculitis that threatens vision today?”

That framing drives modern management. The 2021 American College of Rheumatology/Vasculitis Foundation guideline emphasizes rapid glucocorticoid treatment when giant cell arteritis is strongly suspected, especially with threatened vision. EULAR imaging recommendations also support early ultrasound, MRI, CT angiography, or PET when available, but imaging should not delay treatment in high-risk presentations.

What giant cell arteritis is doing

Giant cell arteritis, or GCA, is a granulomatous vasculitis, meaning immune cells invade and inflame the artery wall. It often affects branches of the external carotid artery, including the temporal artery, but it is better understood as systemic large-vessel disease. The aorta and its branches may be involved even when temple symptoms dominate.

The danger comes from swelling within the vessel wall and narrowing of the lumen, the channel carrying blood. When blood flow to the optic nerve or retina drops, vision loss can occur abruptly and may become permanent. Clinicians often treat first and confirm with testing in parallel.

Warning signs that should change the tempo

Not every headache after age 50 is GCA, but several features should move the evaluation from routine to urgent. The most important warning signs include:

• New persistent headache, especially temporal or unlike prior headaches
• Scalp tenderness when brushing hair or resting on a pillow
• Jaw or tongue claudication: fatigue or pain with chewing or talking
• Transient visual dimming, double vision, curtain-like loss, or blindness
• Unexplained fever, weight loss, sweats, girdle aching, or profound fatigue
• Arm claudication, asymmetric pressures, bruits, or chest or back pain

Jaw claudication deserves respect. It is more specific for GCA than headache because it reflects ischemia of chewing muscles. A patient who says, “My jaw tires halfway through a sandwich,” is describing something different from temporomandibular joint discomfort.

How clinicians confirm the diagnosis without losing time

The diagnostic process has two jobs: protect the patient from ischemic injury and avoid committing someone unnecessarily to months of immunosuppression. Those goals are not in conflict if testing is organized promptly.

Inflammatory markers are helpful but imperfect. Erythrocyte sedimentation rate and C-reactive protein are often elevated, and thrombocytosis or anemia can support the picture. Normal values lower probability, but do not exclude GCA when the story is compelling.

Temporal artery ultrasound can show a halo sign, a dark ring reflecting vessel wall edema. Temporal artery biopsy remains useful when imaging is unavailable or equivocal, but skip lesions mean a negative biopsy does not always end the discussion. Large-vessel imaging is considered when limb symptoms, bruits, persistent inflammation, or aortic involvement are concerns.

Treatment logic: why steroids start before certainty

The immediate treatment goal is vascular safety. High-dose glucocorticoids rapidly suppress arterial inflammation. If vision is threatened, many clinicians use intravenous methylprednisolone before transitioning to oral prednisone; without cranial ischemia, high-dose oral therapy is common. The regimen depends on severity, comorbidities, and specialist judgment.

The reason is risk asymmetry. A delay in treatment can cost vision; a short course started while diagnostic confirmation proceeds can be adjusted if the evidence points elsewhere. This is not casual steroid use. It is a deliberate response to time-sensitive vascular risk.

Steroid toxicity is real: hyperglycemia, hypertension, mood changes, infection, osteoporosis, cataracts, and myopathy all matter in older adults. Bone protection, vaccination review, glucose and blood pressure monitoring, and infection vigilance are part of good GCA care, not afterthoughts.

Where steroid-sparing therapy fits

Tocilizumab, an interleukin-6 receptor inhibitor, has strengthened the evidence base for relapse prevention and steroid reduction. In the GiACTA trial, patients receiving weekly or every-other-week tocilizumab plus a prednisone taper achieved higher sustained remission rates than patients receiving prednisone taper alone. The ACR/Vasculitis Foundation guideline conditionally recommends tocilizumab with glucocorticoids for many newly diagnosed patients, while recognizing that infection risk, diverticulitis history, lipid changes, cost, and access influence decisions.

Methotrexate has more modest data and may be considered when tocilizumab is not appropriate. The reasoning is individualized: the patient with diabetes, recurrent relapse, or high cumulative steroid exposure may benefit from earlier steroid-sparing therapy, while another patient may not.

A clinical scenario

Consider a 72-year-old with three weeks of new temple headache, scalp tenderness, and jaw fatigue while eating. She reports five minutes of gray vision in one eye that resolved. Her ESR and CRP are high. The transient visual symptom changes everything. Treatment generally begins immediately, while ultrasound or biopsy is arranged and ophthalmology involvement is considered.

Common misconception: no temple swelling, no GCA

A normal-looking temporal artery does not rule out GCA. Some patients present mainly with shoulder and hip stiffness, constitutional symptoms, or large-vessel findings. Conversely, a prominent tender artery is not diagnostic by itself. GCA is a pattern diagnosis: age, symptoms, examination, inflammatory markers, imaging, pathology, and treatment response are interpreted together.

What the evidence supports now

Current evidence supports treating strongly suspected cranial GCA before proof when vision is at risk, confirming the diagnosis with vascular imaging and/or biopsy, and using steroid-sparing therapy selectively to reduce relapse and toxicity. Uncertainty remains around optimal taper speed, duration of tocilizumab, and how best to monitor silent aortic disease after symptoms improve.